BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17216011)

  • 21. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
    Johnson V; Lipton LR; Cummings C; Eftekhar Sadat AT; Izatt L; Hodgson SV; Talbot IC; Thomas HJ; Silver AJ; Tomlinson IP
    J Med Genet; 2005 Oct; 42(10):756-62. PubMed ID: 15788729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Colon carcinoma: molecular diagnosis and therapy].
    Blum HE
    Praxis (Bern 1994); 1997 Sep; 86(39):1504-9. PubMed ID: 9411670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MSI-low, a real phenomenon which varies in frequency among cancer types.
    Halford SE; Sawyer EJ; Lambros MB; Gorman P; Macdonald ND; Talbot IC; Foulkes WD; Gillett CE; Barnes DM; Akslen LA; Lee K; Jacobs IJ; Hanby AM; Ganesan TS; Salvesen HB; Bodmer WF; Tomlinson IP; Roylance RR
    J Pathol; 2003 Nov; 201(3):389-94. PubMed ID: 14595750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hereditary colorectal cancer syndromes.
    Strate LL; Syngal S
    Cancer Causes Control; 2005 Apr; 16(3):201-13. PubMed ID: 15947872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution.
    Höglund M; Gisselsson D; Mandahl N; Johansson B; Mertens F; Mitelman F; Säll T
    Genes Chromosomes Cancer; 2001 Jun; 31(2):156-71. PubMed ID: 11319803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of comorbidity in head and neck cancer.
    Piccirillo JF
    Laryngoscope; 2000 Apr; 110(4):593-602. PubMed ID: 10764003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecule based diagnosis].
    Akaza H; Ichikawa T; Tsuruo T; Shimada Y; Moriwaki H; Mori M; Noguchi S; Nakamura S; Saijo N; Sone S; Isonishi S; Ohashi Y; Hinotsu S; von Euler M; Blackedge G
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):125-33. PubMed ID: 14750337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic aspects of colorectal cancer].
    Abramowicz M
    Rev Med Brux; 2001 Sep; 22(4):A199-202. PubMed ID: 11680173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
    Lu SL; Akiyama Y; Nagasaki H; Saitoh K; Yuasa Y
    Biochem Biophys Res Commun; 1995 Nov; 216(2):452-7. PubMed ID: 7488133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the human genome in cancer with genomic approaches.
    Scheel JR; Kuo MD
    J Vasc Interv Radiol; 2006 Aug; 17(8):1225-33. PubMed ID: 16923971
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing cancer with a blood draw.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(23):1774-5. PubMed ID: 23213181
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.
    Savonarola A; Palmirotta R; Guadagni F; Silvestris F
    Pharmacogenomics J; 2012 Aug; 12(4):277-86. PubMed ID: 22760589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer.
    Roukos DH
    Expert Rev Mol Diagn; 2013 Jan; 13(1):1-4. PubMed ID: 23256697
    [No Abstract]   [Full Text] [Related]  

  • 38. High-throughput mutational analysis of the human cancer genome.
    Ma PC; Zhang X; Wang ZJ
    Pharmacogenomics; 2006 Jun; 7(4):597-612. PubMed ID: 16753007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of the protein microarray technique and usefulness in individualized molecular tumor therapy]].
    Espina V
    Onkologie; 2005 Oct; 28 Suppl 4():40-2. PubMed ID: 16205105
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacogenomic contribution to drug response.
    Watson RG; McLeod HL
    Cancer J; 2011; 17(2):80-8. PubMed ID: 21427551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.